Another type can start to gain ground
Por dezesseis anos, o Brasil conteve parte do sofrimento causado pela bactéria Streptococcus pneumoniae com uma vacina de dez cepas — e os resultados foram notáveis. Mas a natureza, como costuma fazer, encontrou seus próprios caminhos: cepas não cobertas avançaram, e os casos de meningite pneumocócica em crianças voltaram a crescer. Em junho, o país responde com uma formulação de vinte cepas, dobrando a proteção e reconhecendo que a saúde pública é menos uma vitória definitiva do que uma conversa contínua com o mundo microbiano.
- Após anos de queda, os casos de meningite pneumocócica em crianças menores de cinco anos subiram de uma média de 164 para 211 por ano — um sinal de alerta que não podia ser ignorado.
- Quase 40% dos casos graves entre 2018 e 2023 foram causados por cepas que a vacina antiga simplesmente não cobria, expondo uma lacuna crescente na proteção.
- O fenômeno de substituição de sorotipos — em que bactérias não vacinadas ocupam o espaço deixado pelas controladas — transformou um sucesso epidemiológico em um novo desafio.
- A VPC20 entra em cena cobrindo exatamente as cepas que passaram a predominar, com potencial de interromper também a transmissão e gerar proteção indireta na população.
- A transição será gradual e com esquemas mistos, mas a meta é clara: substituir completamente a formulação antiga assim que os estoques se esgotarem em todo o país.
A partir de junho, o Brasil começa a substituir a vacina pneumocócica que usou por dezesseis anos por uma versão duas vezes mais abrangente. A nova VPC20, ou Pneumo 20, cobre vinte cepas da bactéria Streptococcus pneumoniae — o dobro da formulação anterior. O Ministério da Saúde divulgou orientações técnicas para os profissionais de saúde, e os municípios poderão começar a aplicar a nova vacina assim que os estoques chegarem.
A doença pneumocócica vai de infecções leves, como otite e sinusite, até condições graves como pneumonia bacteriana, meningite e sepse. Em crianças, a bactéria é responsável por cerca de metade dos casos de meningite bacteriana — e quando a meningite se instala, a mortalidade gira em torno de trinta por cento.
Quando a vacina de dez cepas foi introduzida no calendário infantil em 2010, os resultados foram expressivos: quedas de sessenta a sessenta e cinco por cento nos casos em crianças pequenas. Mas o cenário mudou. Entre 2013 e 2019, o Brasil registrava em média 164 casos anuais de meningite pneumocócica em menores de cinco anos. Entre 2022 e 2024, essa média subiu para 211 — uma reversão preocupante.
A explicação está no que especialistas chamam de substituição de sorotipos: ao controlar as dez cepas vacinadas, outras — não cobertas — foram ocupando o espaço. Dados do Ministério mostram que quase 40% dos casos graves entre 2018 e 2023 foram causados por apenas dois tipos bacterianos ausentes da vacina antiga, mas presentes na nova. A VPC20 também impede que a bactéria se instale na nasofaringe, reduzindo a transmissão e gerando proteção indireta.
A transição será feita em etapas: bebês receberão a nova vacina aos dois e quatro meses, com esquemas mistos durante o período de adaptação, e reforço aos doze meses com a nova formulação. Crianças que já iniciaram o esquema antigo completarão com a VPC20. O calendário padrão prevê duas doses aos dois e quatro meses e um reforço aos doze — e qualquer criança menor de cinco anos com o esquema incompleto deve atualizar a caderneta o quanto antes.
Starting in June, Brazil's public health system will begin rolling out a significantly more protective vaccine against pneumococcal disease, replacing the version it has used for the past sixteen years. The new 20-valent pneumococcal conjugate vaccine—known as VPC20 or Pneumo 20—will cover twice as many bacterial strains as its predecessor, the 10-valent formulation. The Health Ministry released preliminary technical guidance on Wednesday for health professionals implementing the change, with municipalities able to begin administering the new vaccine as soon as supplies arrive.
Pneumococcal disease, caused by the bacterium Streptococcus pneumoniae, ranges from mild infections like ear inflammation and sinusitis to severe conditions including bacterial pneumonia, meningitis, and sepsis. The bacterium is responsible for roughly half of all bacterial meningitis cases in children, and when meningitis develops, the mortality rate hovers around thirty percent. Young children, elderly people, and those with chronic conditions or compromised immune systems face the highest risk.
When Brazil introduced the 10-valent vaccine into its childhood immunization schedule in 2010, the results were dramatic. Cases of meningococcal disease caused by the ten covered strains dropped sixty percent in children under two, while pneumococcal meningitis in the same age group fell sixty-five percent. But in recent years, the picture has shifted. Between 2013 and 2019, Brazil averaged 164 annual cases of pneumococcal meningitis in children under five. From 2022 to 2024, that average climbed to 211 cases per year—a troubling reversal of the earlier gains.
The reason, according to Flávia Bravo, director of the Brazilian Society of Immunizations, lies in an epidemiological phenomenon known as serotype replacement. As the vaccine successfully suppressed the ten covered bacterial types, other strains—ones the vaccine couldn't prevent—began filling the ecological space left behind. "The 10-valent vaccine was excellent at reducing those ten types, which represented an important drop in serious disease," Bravo explained. "But pneumococcus has this characteristic we call replacement: when you control one type and reduce its circulation, another type can start to gain ground." Health Ministry surveillance data shows that nearly forty percent of severe cases with samples collected between 2018 and 2023 were caused by just two bacterial types not covered by the old vaccine but included in the new formulation. Among infants under one year old, about eleven percent of meningitis cases were caused by additional strains now protected against by VPC20.
The conjugate vaccines—both the old and new versions—work in a particularly elegant way. They don't just prevent disease in vaccinated individuals; they also prevent the pneumococcus from establishing itself in the nasopharynx, the back of the nose and throat. This means vaccinated people can't transmit the bacteria as easily, creating indirect protection for those who haven't been vaccinated. "This means we have the possibility of reducing the incidence curve again because we'll be protecting exactly against the serotypes that currently prevail," Bravo said.
The transition will unfold in stages. Infants will receive the new vaccine at their two-month and four-month appointments, with the old 10-valent vaccine at the second dose during the transition period, then the new vaccine again at the twelve-month booster. Children who already received their first dose of the old vaccine will get the new one for their second dose and booster. Any child under five who completed the basic two-dose schedule with the old vaccine will also receive a booster of the new formulation. The Health Ministry already offers more comprehensive pneumococcal vaccines—the 13-valent and 23-valent formulations—but only to specific high-risk groups: people living with HIV, cancer patients, organ and bone marrow transplant recipients, those with chronic kidney, lung, heart, or liver disease, people with severe asthma or diabetes, those with Down syndrome, and premature infants. These older vaccines will eventually be replaced by the 20-valent version once current stocks are depleted.
The standard childhood schedule calls for two doses of pneumococcal vaccine at two and four months, with a booster at twelve months. Any child under five who missed these appointments should update their vaccination record as soon as possible. The vaccine carries no contraindications except for those with severe allergies to any component or a history of severe allergic reaction to previous doses. Anyone running a fever should wait until they recover before being vaccinated. As the new vaccine rolls out across Brazil's twenty-six states and federal district, the question is whether this expanded protection will finally bend the rising curve of pneumococcal disease back downward.
Citações Notáveis
The 10-valent vaccine was excellent at reducing those ten types, but when you control one type and reduce its circulation, another type can start to gain ground— Flávia Bravo, director of the Brazilian Society of Immunizations
We have the possibility of reducing the incidence curve again because we'll be protecting exactly against the serotypes that currently prevail— Flávia Bravo, director of the Brazilian Society of Immunizations
A Conversa do Hearth Outra perspectiva sobre a história
Why did cases start rising again if the vaccine was working so well?
Because the vaccine was working. When you eliminate the ten types it covered, the bacteria that survived—the ones it couldn't stop—suddenly had room to spread. It's like clearing weeds from a garden; other plants move in.
So the new vaccine is basically playing catch-up with the bacteria?
Exactly. The surveillance data showed that nearly forty percent of the severe cases in recent years were caused by just two types that the old vaccine never touched. The new one does. It's not that the old vaccine failed; it's that the bacteria adapted.
What happens to people who already got the old vaccine?
They're not left unprotected. Children who got the old vaccine will receive boosters with the new one. Adults in high-risk groups—people with HIV, cancer patients, transplant recipients—will transition to the new vaccine as supplies of the old ones run out.
Does the vaccine actually stop transmission, or just prevent disease?
Both. These conjugate vaccines prevent the bacteria from settling in the nose and throat, which means vaccinated people are much less likely to carry and spread it. That protects people who can't be vaccinated.
What's the risk if someone doesn't get vaccinated?
For a young child, pneumococcal meningitis carries about a thirty percent mortality rate. Even survivors often face permanent neurological damage. The bacteria causes roughly half of all bacterial meningitis cases in children.
When does this actually start happening?
June. Municipalities will begin administering the new vaccine as soon as they receive it. During the transition, schedules will be mixed—some doses of the new vaccine, some of the old—until the old supplies are gone.